Is preexisting immunity to seasonal coronaviruses limited to cross-reactivity with SARS-CoV-2? A seroprevalence cross-sectional study in north-eastern France.

Zedan, Hadeel T; Nasrallah, Gheyath K

Zedan, Hadeel T; Nasrallah, Gheyath K.

Zedan HT; Department of Biomedical Science, College of Health Sciences, Member of QU Health, Qatar University, P.O. Box 2713, Doha, Qatar; Biomedical Research Center, Qatar University, Doha, Qatar.
Nasrallah GK; Department of Biomedical Science, College of Health Sciences, Member of QU Health, Qatar University, P.O. Box 2713, Doha, Qatar; Biomedical Research Center, Qatar University, Doha, Qatar. Electronic address: gheyath.nasrallah@qu.edu.qa.

EBioMedicine ; 71: 103580, 2021 Sep.

Article in English | MEDLINE | ID: covidwho-1408845

Subject(s)

Antibodies, Viral/immunology; COVID-19/immunology; SARS-CoV-2/immunology; Spike Glycoprotein, Coronavirus/immunology; COVID-19/epidemiology; COVID-19/prevention & control; COVID-19/virology; Cross Reactions/immunology; Cross-Sectional Studies; France/epidemiology; Humans; SARS-CoV-2/pathogenicity; Seasons; Seroepidemiologic Studies; Spike Glycoprotein, Coronavirus/genetics

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Spike Glycoprotein, Coronavirus / SARS-CoV-2 / COVID-19 / Antibodies, Viral Type of study: Observational study / Randomized controlled trials Limits: Humans Country/Region as subject: Europa Language: English Journal: EBioMedicine Year: 2021 Document Type: Article Affiliation country: J.ebiom.2021.103580

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google